The UK-based company Johnson Matthey has announced the sale of its medical device components (MDC) unit to the private equity firm Montagu for £550 million as part of its strategic plan to refine operational focus. Montagu, known for its diverse industry portfolio, is excited about the acquisition and aims to support MDC’s growth in the healthcare sector.
Johnson Matthey, a UK-based company, has announced the sale of its medical device components (MDC) unit to the private equity firm Montagu for £550 million. This decision is part of Johnson Matthey’s strategic plan introduced two years ago, aiming to refine its operational focus. The MDC unit, which boasts manufacturing facilities in the US, Mexico, and Australia, specializes in producing precision-engineered components for medical devices.
Montagu, with a portfolio that includes a variety of industries such as healthcare, defence, and food, has expressed excitement about the acquisition. Adrien Sassi, a partner at Montagu, praised MDC’s capabilities and potential for growth in its sector. Similarly, Don Freeman, CEO of Johnson Matthey, views the acquisition as an opportunity for MDC to enhance its development through organic growth and potential mergers and acquisitions, under the support of Montagu.
This sale not only signifies Johnson Matthey’s continued effort to streamline its operations but also Montagu’s commitment to investing in the healthcare sector and supporting MDC’s ambition to expand its market presence.
